RVPH Quote, Financials, Valuation and Earnings

NanoViricides, Inc. has a net margin of -- compared to Reviva Pharmaceuticals Holdings, Inc.'s net margin of --. Reviva Pharmaceuticals Holdings, Inc.'s return on equity of -- beat NanoViricides, Inc.'s return on equity of -92.29%.

Reviva Pharmaceuticals Holdings, Inc. has a consensus price target of $5.00, signalling upside risk potential of 734.86%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 424.19%. Given that Reviva Pharmaceuticals Holdings, Inc. has higher upside potential than NanoViricides, Inc., analysts believe Reviva Pharmaceuticals Holdings, Inc. is more attractive than NanoViricides, Inc..

Reviva Pharmaceuticals Holdings, Inc. has a beta of -0.026, which suggesting that the stock is 102.568% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.

Reviva Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reviva Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.

Reviva Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Reviva Pharmaceuticals Holdings, Inc.'s net income of -$4M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Reviva Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reviva Pharmaceuticals Holdings, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics, Inc. has a net margin of -- compared to Reviva Pharmaceuticals Holdings, Inc.'s net margin of --. Reviva Pharmaceuticals Holdings, Inc.'s return on equity of -- beat Oragenics, Inc.'s return on equity of -509.23%.

Reviva Pharmaceuticals Holdings, Inc. has a consensus price target of $5.00, signalling upside risk potential of 734.86%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 127.84%. Given that Reviva Pharmaceuticals Holdings, Inc. has higher upside potential than Oragenics, Inc., analysts believe Reviva Pharmaceuticals Holdings, Inc. is more attractive than Oragenics, Inc..

Reviva Pharmaceuticals Holdings, Inc. has a beta of -0.026, which suggesting that the stock is 102.568% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.

Reviva Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reviva Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.

Reviva Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Reviva Pharmaceuticals Holdings, Inc.'s net income of -$4M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Reviva Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reviva Pharmaceuticals Holdings, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Reviva Pharmaceuticals Holdings, Inc.'s net margin of --. Reviva Pharmaceuticals Holdings, Inc.'s return on equity of -- beat Palatin Technologies's return on equity of --.

Reviva Pharmaceuticals Holdings, Inc. has a consensus price target of $5.00, signalling upside risk potential of 734.86%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Reviva Pharmaceuticals Holdings, Inc., analysts believe Palatin Technologies is more attractive than Reviva Pharmaceuticals Holdings, Inc..

Reviva Pharmaceuticals Holdings, Inc. has a beta of -0.026, which suggesting that the stock is 102.568% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Reviva Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reviva Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Reviva Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Reviva Pharmaceuticals Holdings, Inc.'s net income of -$4M is higher than Palatin Technologies's net income of --. Notably, Reviva Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reviva Pharmaceuticals Holdings, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -- compared to Reviva Pharmaceuticals Holdings, Inc.'s net margin of --. Reviva Pharmaceuticals Holdings, Inc.'s return on equity of -- beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Reviva Pharmaceuticals Holdings, Inc. has a consensus price target of $5.00, signalling upside risk potential of 734.86%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3570.69%. Given that Theriva Biologics, Inc. has higher upside potential than Reviva Pharmaceuticals Holdings, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Reviva Pharmaceuticals Holdings, Inc..

Reviva Pharmaceuticals Holdings, Inc. has a beta of -0.026, which suggesting that the stock is 102.568% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Reviva Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reviva Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Reviva Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Reviva Pharmaceuticals Holdings, Inc.'s net income of -$4M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Reviva Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reviva Pharmaceuticals Holdings, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.